Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
Ruth J. Pepper(The Royal Free Hospital), Alan D. Salama(The Royal Free Hospital), Margarete A. Fabre(University of Cambridge), Rachel Jones(University of Cambridge), David Jayne(University of Cambridge), Charles D. Pusey(Imperial College Healthcare NHS Trust), G. Gaskin(Hammersmith Hospital), Carlos Pavésio(Moorfields Eye Hospital NHS Foundation Trust)
Cited by 149
Related Papers
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
Avacopan for the Treatment of ANCA-Associated Vasculitis
|New England Journal of Medicine|2021|957
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726